Valuation: Savara Inc

Market Cap 1.26B 1.13B 1.04B 941M 1.76B 120B 1.79B 12.4B 4.95B 62.69B 4.72B 4.62B 199B P/E 2026 *
-8.2x
P/E 2027 * -12.7x
Enterprise Value 792M 709M 654M 592M 1.11B 75.4B 1.13B 7.81B 3.11B 39.46B 2.97B 2.91B 125B EV / Sales 2026 *
441x
EV / Sales 2027 * 11.7x
Free-Float
97.45%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2020
Director of Finance/CFO 57 15/07/2026
Chief Tech/Sci/R&D Officer 56 01/12/2023
Director TitleAgeSince
Director/Board Member 59 01/02/2009
Director/Board Member 77 01/10/2010
Director/Board Member 73 01/10/2013
Change 5-day change 1-year change 3-year change Capi.($)
+0.34%+1.12%+34.75%+61.06% 64.38B
-0.12%+2.71%+14.38%+83.68% 56.16B
+1.23%+2.56%+16.05%+108.03% 54.16B
-1.43%-1.17%+26.27%+52.86% 45.33B
-0.48%-2.80%+18.01%+117.99% 42.25B
+0.82%+1.37%+227.94%+922.41% 40.78B
+0.88%+43.80%+106.69%+90.96% 33.8B
-0.26%-2.57%+12.55%+45.18% 32.25B
-1.29%-2.88%+21.60%-11.92% 23.57B
Average +0.16%+4.50%+53.14%+163.36% 43.63B
Weighted average by Cap. +0.26%+3.60%+50.12%+162.30%

Financials

2026 *2027 *
Net sales 1.8M 1.61M 1.48M 1.34M 2.51M 171M 2.55M 17.7M 7.06M 89.46M 6.74M 6.59M 283M 79.65M 71.34M 65.82M 59.56M 111M 7.58B 113M 785M 313M 3.97B 299M 293M 12.57B
Net income -151M -135M -125M -113M -211M -14.37B -214M -1.49B -593M -7.52B -566M -554M -23.81B -94.11M -84.3M -77.77M -70.38M -132M -8.96B -134M -928M -370M -4.69B -353M -346M -14.86B
Net Debt -466M -418M -385M -349M -652M -44.39B -662M -4.6B -1.83B -23.23B -1.75B -1.71B -73.58B -329M -294M -271M -246M -459M -31.28B -467M -3.24B -1.29B -16.37B -1.23B -1.21B -51.85B
Logo Savara Inc
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company's lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Savara Inc